OrbiMed Advisors »

Ataibeckley shares owned by OrbiMed Advisors

Quarter-by-quarter ownership of Ataibeckley (ATAI) shares owned by OrbiMed Advisors from 13F filings

Historical chart of OrbiMed Advisors investment in Ataibeckley

Tip: Access up to 7 years of quarterly data

All positions including Ataibeckley held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ataibeckley by OrbiMed Advisors

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.2M 347k 3.54

More positions owned by OrbiMed Advisors

Edgewise Therapeutics (EWTX)
Enliven Therapeutics (ELVN)
Avita Therapeutics (RCEL)
Mdxhealth Sa Shs New Call Option (MDXH)
Eli Lilly & Co. (LLY)
Sinovac Biotech SHS
Boston Scientific Corporation (BSX)
Sionna Therapeutics (SION)
Astrazeneca Ord (AZN)
Myriad Genetics (Principal) (MYGN)
Mbx Biosciences (MBX)
Corvus Pharmaceuticals (CRVS)
Argenx Se Sponsored Adr (ARGX)
Edwards Lifesciences (EW)
Intuitive Surgical Com New (ISRG)

View all positions for OrbiMed Advisors

Top funds holding Ataibeckley

Deep Track Capital
Vanguard Capital Management
UBS Group
BlackRock
Millennium Management
Morgan Stanley
Candriam Luxembourg S.C.A.
Foresite Capital Management VI
Marshall Wace
Geode Capital Management
Two Sigma Investments
Newtyn Management
Eagle Health Investments
Vanguard Fiduciary Trust
Moore Capital Management

View all funds holding Ataibeckley